betamethasone dipropionate · Primus Pharms · NDA 208079
Sernivo
Earliest generic entry, as listed
19 Nov 2045
Blocked by patent: US 12661489. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12661489 | use U-4596 | 19 Nov 2045 |
| US 10179137 | product, use U-1858 | 31 Aug 2030 |
| US 9364485 | product, use U-1858 | 31 Aug 2030 |
| US 9433630 | product, use U-1858 | 31 Aug 2030 |
| US 9439911 | product, use U-1858 | 31 Aug 2030 |
| US 9655907 | product, use U-1858 | 31 Aug 2030 |
| US 9775851 | product, use U-1858 | 31 Aug 2030 |
| US 9877974 | product, use U-1858 | 31 Aug 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208079 · 001 · RLD | spray, topical | EQ 0.05% BASE/SPRAY | 19 Nov 2045 |